首页
热心肠日报
文献库
产业库
榜单
关于日报
《肠·道》演讲
往期精彩
《肠·道》2024
《肠·道》2023
《肠·道》2022
《肠·道》2021
《肠·道》2020
《肠·道》2019
《肠·道》2018
《肠·道》2017
关于《肠·道》
肠道大会
热心肠大会
热心肠智库
智库专家
专家动态
智库新闻
关于智库
奖学金
年度人物奖
更多
HOPE
会议信息
科学与艺术
学术专刊
R·AI
周刊
热心肠先生
研究院动态
关于我们
搜索
登录
关闭
手机邮箱登录
扫码登录
微信扫描二维码快捷登录
验证成功，将在
3
秒钟后跳转
已超时，请
重试
关闭
二维码登录
手机登录
邮箱登录
+86
+1
+852
+886
+81
+65
+61
+44
获取验证码
登录 / 注册
关闭
二维码登录
手机登录
邮箱登录
获取验证码
登录 / 注册
热心肠智库
专家文章 | 邱正堂
2022
CA
Gut Colonization and Antibiotic-Associated Diarrhea by Clostridium innocuum in Children and Adults
Clin Infect Dis, 10.1093/cid/ciac696
2021
CA
The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study
Taiwan yi zhi, 10.1016/j.jfma.2021.11.012
CA
Implementation of fecal microbiota transplantation in a medical center for recurrent or refractory Clostridioides difficile infection and report of preliminary outcome
BIOMED J, 10.1016/j.bj.2021.06.001
CA
Multidrug resistance: The clinical dilemma of refractory Helicobacter pylori infection
J MICROBIOL IMMUNOL, 10.1016/j.jmii.2021.03.006
2020
CA
Fecal microbiota transplantation and donor screening for Clostridioides difficile infection during COVID-19 pandemic
Taiwan yi zhi, 10.1016/j.jfma.2020.07.028
CA
Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains
BMC Gastroenterol, 10.1186/s12876-020-01370-4
CA
Drug-Resistant Bacteremia after Fecal Microbiota Transplant
NEJM, 10.1056/NEJMc2002496#sa2
2019
CA
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for infections
THER ADV GASTROENTER, 10.1177/1756284819870960
CA
Efficacy of dexlansoprazole-based triple therapy for infections
THER ADV GASTROENTER, 10.1177/1756284819870960
